Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Pharmacia Invests in Informax - Test

NEW YORK, Sept 6  Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.

The deal represents the largest collaboration for InforMax of Rockville, Md., to date.

Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.

The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.

The companies will share the proceeds from marketing and distributing the new product.

“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said

What do you think in a statement. " I like it!"

Amersham could not immediately be reached for comment.

A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.

NEW YORK, Sept 6 – Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.

 

The deal represents the largest collaboration for InforMax of Rockville, Md., to date.

 

Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.

 

The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.

 

The companies will share the proceeds from marketing and distributing the new product.

 

“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said in a statement.

 

Amersham could not immediately be reached for comment.

 

A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.